Common misconceptions

Common mistake
Gap: Missing that finasteride halves PSA, requiring correction when interpreting prostate cancer screening
Finasteride reduces serum PSA by approximately 50%, so a measured PSA must be doubled to estimate the true value when screening for prostate cancer in patients on finasteride.
Finasteride shrinks prostatic epithelium by depleting DHT, and as a side effect it reduces PSA secretion by roughly half — even in the presence of early prostate cancer. If you read a PSA of 2 ng/mL at face value in a patient on finasteride, you're effectively ignoring a true value closer to 4 ng/mL. The clinical rule is simple: double the measured PSA before interpreting it in any patient on 5α-reductase inhibitors.
Common mistake
Wrong: Finasteride blocks the androgen receptor directly like flutamide.
Right: Finasteride inhibits 5α-reductase, preventing conversion of testosterone to the more potent DHT, rather than blocking the androgen receptor.
Finasteride works upstream of the androgen receptor — it inhibits the enzyme 5α-reductase, blocking the conversion of testosterone to DHT. Flutamide and bicalutamide are androgen receptor antagonists that work downstream by competing with DHT for receptor binding. These are completely different mechanisms, and the distinction matters: finasteride doesn't block all androgenic activity, just the DHT-dependent portion, which is why testosterone levels actually rise slightly on finasteride.
Common mistake
Gap: Missing that finasteride poses teratogenic risk to male fetuses via skin contact in pregnant women
Finasteride is teratogenic to male fetuses (inhibits virilization) and pregnant women must not handle crushed tablets due to transdermal absorption risk.
DHT is required during fetal development for differentiation of male external genitalia from the urogenital sinus and tubercle. If a pregnant woman is exposed to finasteride — even through skin contact with a crushed tablet — enough drug can be absorbed transdermally to inhibit 5α-reductase in a male fetus, resulting in ambiguous genitalia or undervirilization. This is why finasteride tablets are film-coated and why pregnant women are instructed to avoid handling broken or crushed tablets entirely.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Understand the mechanism of 5α-reductase inhibitors: they prevent conversion of testosterone to DHT at the enzyme level, which is distinct from androgen receptor blockers like flutamide that work downstream at the receptor.
  2. Know how finasteride affects PSA interpretation: because it suppresses PSA by approximately 50%, a measured PSA on a patient taking finasteride must be doubled to estimate the true baseline value for prostate cancer screening purposes.
  3. Recognize the teratogenic risk of finasteride to male fetuses and understand that pregnant women must not handle crushed or broken tablets due to the risk of transdermal absorption causing impaired virilization.

Can you avoid these mistakes?

A 62-year-old man with BPH has been taking finasteride for 2 years. His PSA comes back at 2.8 ng/mL. His urologist says this is reassuring. Is the urologist correct, and what is the appropriate way to interpret this value?
How does finasteride's mechanism differ from flutamide's? What happens to serum testosterone levels in a patient taking finasteride, and why?
A pregnant woman calls her OB saying she accidentally broke her husband's finasteride tablet while organizing his medications and may have touched the powder. Should she be concerned? What is the relevant risk and why?
A patient is started on finasteride for androgenetic alopecia. Six months later his PSA is measured for the first time as part of a routine screen and is 1.4 ng/mL. What value should be used to interpret his prostate cancer risk?

Related topics

See how your Anki deck covers this topic.

Upload your deck for a free audit →